An interventional study of Blood sample and Urine sample in Malaria and Bacterial Co-infection, sponsored by Institut Pasteur. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-01-24.
Sponsored by Institut Pasteur · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Few studies have focused on malaria co-infections, mainly caused by Plasmodium falciparum, occurring mainly in children under 5 years of age in sub-Saharan Africa. These studies have focused on malaria-associated bacterial sepsis, with an estimated prevalence of 9.1% and associated mortality of 15.0%. However, no study has documented infectious sites other than the blood compartment, considered viruses and parasites as possible causes of infection in addition to bacteria, and used molecular diagnostic methods based on PCRs, which are more sensitive. Thus, the prevalence of these co-infections and the spectrum of pathogens involved are probably underestimated, as is the impact of these co-infections on mortality. Furthermore, it has been shown that malaria infections can condition the immune cells of naturally exposed individuals, potentially leading to greater susceptibility to all types of infection. But these mechanisms have never been documented in the context of co-infections.
The WHO recommends the use of broad-spectrum antibiotics in cases of severe malaria, in addition to antimalarial drugs, as it can be difficult to differentiate clinically between severe malaria and severe bacterial infection (bacteremia, pneumonia and meningitis). Yet this empirical use of antibiotics could be contributing to an increase in antibiotic resistance. Identifying the determinants of co-infection with malaria and severe bacterial infection would enable this treatment to be better targeted.
These determinants remain undetermined as no study has considered other causes of severe bacterial infection other than bacteremia, used appropriate statistical methodology (univariate analysis only) and explored important determinants, notably the capacity of children's innate immunity to respond to severe bacterial infection.
This is a prospective multicenter longitudinal study.
The study will focus on several populations:
The study will be based on :
1,186 studies on the registry are indexed under Malaria; 80 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 252 across 939 interventional studies indexed under Malaria.
Browse Malaria studies →Institut Pasteur is the lead sponsor of 99 studies on the registry; 41 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Febrile children:
Non-febrile children:
Pregnant women :
Newborns at delivery:
Exclusion Criteria:
For all :
For febrile and non-febrile children:
For pregnant women
The study population is composed of children under the age of 5, which is also the population most at risk of malaria, living in the endemic areas of Lomé and Tsévié in Togo.
Other: Blood sample · Other: Urine sample · Other: oropharyngeal sample · Other: Optionnal : stool sample · Other: Optionnal : cerebrospinal fluid · Other: placental biopsy
For febrile children at the time of inclusion : 6.25 ml to 8.25 ml of blood ; For non febrile children at the time of inclusion : 4 ml of blood ; For pregnant women at the time of inclusion : 5 ml of peripheral blood, 5 ml of placental blood, 20 to 40 ml of umbilical cord blood ; For new borns : drop of blood on child's heel each month and 5 ml of blood the 12th and last month.
For febrile children : 10 ml of urine
For febrile children : oropharyngeal swab sampling
For febrile children (only as part of the care of the child) : 5g stool
For febrile children (only as part of the care of the child in case of suspected meningitis) : 4 additional drops of cerebrospinal fluid
For pregnant women : placental biopsy the size of 2 rice grains
Determine the extent and microbiological spectrum of malaria co-infections in children under 5.
the number of malaria co-infection events in febrile children.
Time frame: 3 years
Assess the impact of malaria co-infections on mortality
Number of deaths in children under 5 with malaria co-infection
Time frame: 2 years
Identify the underlying immunological mechanisms mediating malaria co-infections
Concentration of cytokines IL6, IL1β and TNFα and IL 10 in children under 5 years of age
Time frame: 2 years
Identify epigenetic and transcriptomic modifications in infant, maternal and placental blood cells mediating malaria co-infections
Expression level of transcripts according to the populations studied will be measured by RNA-seq
Time frame: 2 years
Identify molecules associated with epigenetic modifications (metabolome, proteome).
Expression level of proteins and metabolites according to the populations studied will be measured by RNA-seq
Time frame: 2 years
Identify determinants of malaria co-infections and severe bacterial infections.
The number of malaria co-infection events associated with severe bacterial infection in febrile children under 5 years of age.
Time frame: 2 years
No study locations are listed for this record.
Start is estimated for Feb 2025; primary completion for Feb 2027, 24 months later.
Of 102 interventional studies with no phase under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 24 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.